Everbridge, Inc. (EVBG) Reaches $44.31 52-Week High; Cytokinetics (CYTK) Sentiment Is 1.11

May 22, 2018 - By Migdalia James

Cytokinetics, Incorporated (NASDAQ:CYTK) Logo

The stock of Everbridge, Inc. (NASDAQ:EVBG) hit a new 52-week high and has $46.08 target or 4.00% above today’s $44.31 share price. The 7 months bullish chart indicates low risk for the $1.27B company. The 1-year high was reported on May, 22 by Barchart.com. If the $46.08 price target is reached, the company will be worth $50.96M more. The stock decreased 0.17% or $0.075 during the last trading session, reaching $44.305. About 38,839 shares traded. Everbridge, Inc. (NASDAQ:EVBG) has risen 84.00% since May 22, 2017 and is uptrending. It has outperformed by 72.45% the S&P500.

Cytokinetics Inc (CYTK) investors sentiment decreased to 1.11 in 2017 Q4. It’s down -0.28, from 1.39 in 2017Q3. The ratio dropped, as 60 institutional investors started new and increased holdings, while 54 sold and reduced holdings in Cytokinetics Inc. The institutional investors in our database reported: 38.16 million shares, down from 39.12 million shares in 2017Q3. Also, the number of institutional investors holding Cytokinetics Inc in top ten holdings increased from 0 to 1 for an increase of 1. Sold All: 15 Reduced: 39 Increased: 36 New Position: 24.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company has market cap of $468.16 million. The firm is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. It currently has negative earnings. The Company’s lead drug candidate is Tirasemtiv, a fast skeletal troponin activator, which is in Phase III clinical trial in patients with amyotrophic lateral sclerosis.

More notable recent Cytokinetics, Incorporated (NASDAQ:CYTK) news were published by: Globenewswire.com which released: “Cytokinetics, Inc. Reports First Quarter 2018 Financial Results” on April 26, 2018, also Globenewswire.com with their article: “Cytokinetics to Hold Annual Meeting of Stockholders” published on May 10, 2018, Nasdaq.com published: “Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal …” on April 24, 2018. More interesting news about Cytokinetics, Incorporated (NASDAQ:CYTK) were released by: Seekingalpha.com and their article: “Cytokinetics’ (CYTK) CEO Robert Blum on Q1 2018 Results – Earnings Call Transcript” published on April 27, 2018 as well as Investingnews.com‘s news article titled: “Cytokinetics Reports First Quarter 2018 Financial Results” with publication date: April 27, 2018.

The stock decreased 0.14% or $0.01 during the last trading session, reaching $8.64. About 10,741 shares traded. Cytokinetics, Incorporated (CYTK) has declined 40.55% since May 22, 2017 and is downtrending. It has underperformed by 52.10% the S&P500.

Analysts await Cytokinetics, Incorporated (NASDAQ:CYTK) to report earnings on August, 1. They expect $-0.51 earnings per share, up 15.00% or $0.09 from last year’s $-0.6 per share. After $-0.56 actual earnings per share reported by Cytokinetics, Incorporated for the previous quarter, Wall Street now forecasts -8.93% EPS growth.

Ratings analysis reveals 100% of Cytokinetics’s analysts are positive. Out of 2 Wall Street analysts rating Cytokinetics, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $21.0 while the high is $22.0. The stock’s average target of $21.50 is 148.84% above today’s ($8.64) share price. CYTK was included in 2 notes of analysts from December 16, 2016. Cantor Fitzgerald initiated it with “Overweight” rating and $21.0 target in Friday, December 16 report. Needham upgraded the stock to “Strong Buy” rating in Monday, February 6 report.

Since January 1, 0001, it had 0 insider purchases, and 3 insider sales for $87,976 activity.

Bvf Inc Il holds 5.62% of its portfolio in Cytokinetics, Incorporated for 5.72 million shares. Ironwood Investment Management Llc owns 107,139 shares or 0.62% of their US portfolio. Moreover, Lansdowne Partners (Uk) Llp has 0.2% invested in the company for 2.65 million shares. The Israel-based Sphera Funds Management Ltd. has invested 0.2% in the stock. Wasatch Advisors Inc, a Utah-based fund reported 1.68 million shares.

Analysts await Everbridge, Inc. (NASDAQ:EVBG) to report earnings on August, 2. They expect $-0.44 EPS, down 388.89% or $0.35 from last year’s $-0.09 per share. After $-0.40 actual EPS reported by Everbridge, Inc. for the previous quarter, Wall Street now forecasts 10.00% negative EPS growth.

Among 4 analysts covering Everbridge (NASDAQ:EVBG), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Everbridge has $21 highest and $20 lowest target. $20.50’s average target is -53.73% below currents $44.305 stock price. Everbridge had 5 analyst reports since October 11, 2016 according to SRatingsIntel. The company was initiated on Tuesday, October 11 by Credit Suisse. The stock of Everbridge, Inc. (NASDAQ:EVBG) has “Buy” rating given on Tuesday, October 11 by Bank of America. Pacific Crest initiated the shares of EVBG in report on Tuesday, October 11 with “Overweight” rating. The stock has “Buy” rating by Stifel Nicolaus on Tuesday, October 11.

More recent Everbridge, Inc. (NASDAQ:EVBG) news were published by: Seekingalpha.com which released: “Everbridge: Dominant Company In A Niche Market” on May 21, 2018. Also Globenewswire.com published the news titled: “Report: Exploring Fundamental Drivers Behind Micronet Enertec Technologies, Everbridge, Visteon, Commerce …” on May 17, 2018. Seekingalpha.com‘s news article titled: “Everbridge’s (EVBG) CEO Jaime Ellertson on Q1 2018 Results – Earnings Call Transcript” with publication date: May 08, 2018 was also an interesting one.

Everbridge, Inc., a software company, provides critical communications and enterprise safety applications that enable clients to automate and accelerate the process of keeping people safe and businesses running during critical events. The company has market cap of $1.27 billion. The Company’s SaaS platform enables clients to aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes, and track progress on executing response plans. It currently has negative earnings. The companyÂ’s critical event management platform comprises a set of software applications that address various tasks an organization has to perform to manage a critical event, including Mass Notification, Incident Management, Safety Connection, IT Alerting, Visual Command Center, Crisis Commander, Community Engagement, and Secure Messaging.

Cytokinetics, Incorporated (NASDAQ:CYTK) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>